Patient-reported outcomes in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study
{{output}}
Background: The treatment of neuromyelitis optica spectrum disorder (NMOSD) has entered the era of targeted biological agents. While relapse control has improved substantially, patient-reported outcomes (PROs) remain understudied... ...
